Table 2.
Summary of MOS-HIV physical and mental health summary scores in NNRTI clinical trials
| Citation | Treatment/dosing regimen | Follow-up period |
Physical health summary scores |
Mental health summary scores |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Baseline |
Follow-up |
Significance |
Baseline |
Follow-up |
Significance |
|||||
| Mean (SD) | Mean | Over time | Between groups | Mean (SD) | Mean | Over time | Between groups | |||
|
Randomized controlled trials | ||||||||||
| Chang et al. (2007) |
Intervention: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to tapes with instructions to elicit the relaxation response via earphones, followed by soft music played in the clinic |
4 weeks |
57.5 (21.1) |
61.3 |
N |
N |
57.5 (17.0) |
62.9 |
Y |
N |
| 8 weeks |
62.7 |
N |
N |
62.8 |
N |
N |
||||
| 12 weeks |
65.6 |
Y |
N |
68.1 |
Y |
N |
||||
| Control: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to soft music played in the clinic |
4 weeks |
62.0 (21.4) |
66.7 |
N |
N |
64.1 (17.9) |
71.0 |
Y |
N |
|
| 8 weeks |
66.4 |
N |
N |
69.5 |
N |
N |
||||
| 12 weeks |
65.7 |
N |
N |
70.7 |
N |
N |
||||
| Bucciardini et al. (2007) |
Didanosine + stavudine + efavirenz |
1 year |
50 (11) |
54.7 |
N |
N |
49 (10) |
53.0 |
N |
N |
| 2 years |
|
54.9 |
N |
N |
|
50.4 |
N |
N |
||
| 3 years |
|
54.9 |
N |
N |
|
49.5 |
N |
N |
||
| Didanosine + stavudine + nelfinavir |
1 year |
46 (13) |
46.7 |
N |
N |
48 (10) |
50.8 |
N |
N |
|
| 2 years |
|
49.2 |
N |
N |
|
51.5 |
N |
N |
||
| 3 years |
|
50.9 |
N |
N |
|
53.5 |
N |
N |
||
| Didanosine + stavudine + efavirenz + nelfinavir |
1 year |
48 (12) |
50.0 |
N |
N |
50 (9) |
50.0 |
N |
N |
|
| 2 years |
48.1 |
N |
N |
49.5 |
N |
N |
||||
| 3 years |
50.0 |
N |
N |
53.4 |
N |
N |
||||
| Huang et al. (2008) |
Tipranavir + ritanovir |
48 weeks |
48.0 (11.3) |
48.2 |
NM |
N |
47.8 (10.5) |
49.2 |
NM |
N |
| Boosted comparitor protease inhibitor |
48 weeks |
47.1 (10.9) |
46.8 |
NM |
N |
46.9 (10.3) |
48.6 |
NM |
N |
|
| Lafaurie et al. (2008) |
Maintenance of a stable protease inhibitor-containing regimen |
48 weeks |
NR |
−1.04 |
NM |
N |
NR |
0.00 |
NM |
N |
| Switch to efavirenz + didanosine + emtricitabine once-daily |
48 weeks |
NR |
−1.76 |
NM |
N |
NR |
1.01 |
NM |
N |
|
| Sprinz et al. (2006) |
Immediate substitution with lopinavir/ritonavir 400/200 mg twice daily |
4 weeks |
49.44 |
52.06 |
Y |
Y |
46.7 |
50.79 |
Y |
Y |
| 8 weeks |
|
52.38 |
Y |
Y |
|
51.34 |
Y |
Y |
||
| Deferred (week 4) substitution with lopinavir/ritonavir 400/100 mg twice daily |
4 weeks |
50.32 |
49.71 |
N |
Y |
48.25 |
48.03 |
N |
Y |
|
| 8 weeks |
51.12 |
N |
Y |
50.02 |
Y |
Y |
||||
| Nuesch et al. (2009) |
Continuous treatment |
24 weeks |
53.8 (6.6) |
52.7 |
N |
N |
51.7 (7.6) |
52.7 |
Y |
Y |
| 48 weeks |
52.5 |
N |
N |
52.5 |
Y |
Y |
||||
| CD4-guided scheduled treatment interruption (CD4 threshold of 350 cells/μL for interruption/re-initiation of ARV therapy) |
24 weeks |
54.4 (6.3) |
53.2 |
N |
N |
49.1 (8.3) |
48.1 |
Y |
Y |
|
| 48 weeks |
53.2 |
N |
N |
49.5 |
Y |
Y |
||||
| Powers et al. (2006) |
Intermittent treatment (7 cycles of 4 weeks off/8 weeks on HAART) |
4 weeks |
54.2 (8.3) |
54.2 |
N |
Y |
54.0 (8.8) |
53.56 |
N |
Y |
| 12 weeks |
|
55.55 |
N |
Y |
|
57.45 |
Y |
Y |
||
| 40 weeks |
|
54.76 |
N |
Y |
|
57.22 |
Y |
Y |
||
| Continuous treatment (continue regimen for 22 weeks) |
4 weeks |
53.0 (11.5) |
53.27 |
N |
Y |
53.8 (15.7) |
53.36 |
N |
Y |
|
| 12 weeks |
|
52.97 |
N |
Y |
|
57.25 |
N |
Y |
||
| 40 weeks |
|
54.00 |
N |
Y |
|
57.02 |
N |
Y |
||
| Wu et al. (2006) |
Disease Management Assistance System + education |
6 months |
45.7 (11.0) |
44.2 |
NR |
Y |
49.2 (10.3)* |
49.5 |
NR |
N |
| Education only |
6 months |
41.2 (12.7) |
47.0 |
NR |
Y |
40.7 (12.4)* |
44.9 |
NR |
N |
|
|
Non-randomized controlled trials |
||||||||||
| Shalit et al. (2007) |
Enfuvirtide + ARTs |
12 weeks |
NR |
2.21 |
Y |
N/A |
NR |
2.91 |
Y |
N/A |
| Levine et al. (2008) |
Epoetin alfa + iron supplementation (in addition to current ART regimen) |
MPD1 |
38.5 (12.0) |
43.0 |
N |
N/A |
42.4 (11.2) |
47.8 |
N |
N/A |
| 24 weeks |
43.5 |
Y |
N/A |
47.5 |
Y |
N/A |
||||
| Stangl et al. (2007) | HAART and weekly home visits by study staff that re-supplied HAART and other drugs, conducted a pill count, and assessed participants’ health | 3 months |
39.2 (9.8) | 50.6 |
Y |
N/A |
40.0 (11.2) | 50.2 |
Y |
N/A |
| 6 months |
53.0 |
Y |
N/A |
53.0 |
Y |
N/A |
||||
| 9 months |
53.6 |
Y |
N/A |
54.2 |
Y |
N/A |
||||
| 12 months | 54.2 | Y | N/A | 54.2 | Y | N/A | ||||
*significant difference in baseline scores (P=0.01).